Malaria prevention study with combined medicines in Ghana
Part of Infections clinical trials.
This trial tests if giving two malaria medicines together (dihydroartemisinin piperaquine and primaquine) to everyone in a community can help reduce malaria. It is for people living in high-risk areas in eastern Ghana.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 3 months old or older.
- You must live in the community for the whole study period.
- If you are under 18, your parent or guardian must sign a consent form.
- If you are 12–17 years old, you must also give your own assent.
- If you are 18 or older, you must sign a consent form yourself.
- You cannot be pregnant, have a life-threatening illness other than malaria, weigh less than 10 kg (or be under 1 year old), have had a bad reaction to primaquine before, or have G6PD deficiency.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to prevent malaria in children living in Busia District, Uganda. It combines malaria vaccines with preventive medicine to see if it offers better protection than current methods.
This trial tests a medicine called tafenoquine, which is used to treat malaria. It aims to see how well it works in children with uncomplicated malaria, and participants will also receive standard malaria treatments.
This study tests different schedules of a malaria prevention medicine to see which works best for improving school attendance, learning, and executive function in children aged 6 to 10 in Siaya County, Kenya.
This study tests how well malaria treatments work in Ethiopia. It aims to find the best medicines for uncomplicated malaria caused by certain parasites, helping patients recover fully and preventing future drug resistance.
This trial tests whether giving a malaria prevention drug (DHA-PQP) to pregnant women in Kasese District can reduce malaria in pregnancy. Pregnant women at Bugoye Health Center who are less than 22 weeks along may join.
This study compares a combination of three medicines to treat uncomplicated malaria, to see if it works as well and is as well tolerated as a two-medicine combination. You may join if you have a specific type of malaria infection in a mild form and meet safety requirements.
Hear when a new Malaria Falciparum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.